Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multivalent COVID-19 inactivated vaccine
- Development stage
- Preclinical
- Lead developer
- Beijing Institute of Biological Products
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The multivalent COVID-19 inactivated vaccine is a candidate developed by the Beijing Institute of Biological Products (BIBP), a subsidiary of Sinopharm (CNBG). This vaccine utilizes inactivated whole-virus particles from multiple strains or variants of the SARS-CoV-2 virus to induce a broad neutralizing antibody response and protective immunity. As an inactivated vaccine, the virus is typically grown in Vero cell cultures and then chemically inactivated, preserving the structural integrity of the viral antigens (such as the spike, nucleocapsid, envelope, and membrane proteins) to stimulate the immune system without the risk of viral replication. This multivalent approach is intended to provide enhanced protection against emerging variants of concern compared to original monovalent formulations. It is currently in the preclinical/development stage.
- Other names
- 多价新冠灭活疫苗多价新冠病毒灭活疫苗Multivalent COVID-19 Inactivated Vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on multivalent COVID-19 inactivated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multivalent COVID-19 inactivated vaccine.